Jessy Edwards  |  June 8, 2021

Category: Legal News

Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.

Opioid Lawsuits Against Marketing Consultant McKinsey Get Own Multidistrict Litigation
(Photo Credit: PureRadiancePhoto/Shutterstock)

A volley of lawsuits brought against a management consulting firm for its role in marketing OxyContin amid the opioid crisis will get their own multidistrict litigation in a California federal court.

On Monday, the Judicial Panel on Multidistrict Litigation ruled that lawsuits about McKinsey & Co.’s role in the opioid crisis — consulting for OxyContin seller Purdue Pharma LP and other drugmakers — would not be added to the existing opioid multidistrict litigation in Ohio. 

It said, even though there were factual overlaps between the McKinsey cases and the cases against drug manufacturers, distributors and pharmacies, the management consultant could be prejudiced by joining the 3.5-year-old litigation at such a late stage.

“Adding a relatively unique defendant such as McKinsey to an already exceedingly complex and contentious MDL may hinder the [existing MDL] judge’s ability to efficiently manage the range of cases now before him,” the panel said.

Instead, the 34 pending lawsuits from cities, counties, tribes and individuals against McKinsey would be heard by Judge Charles R. Breyer, the panel ruled. 

It said Breyer’s previous experience presiding over the “bellwether remand action” City and County of San Francisco, et al. v. Purdue Pharma, L.P., et al. gave him “granular insight into the federal opioid litigation that few other judges have obtained.”

The centralization of all of the actions against McKinsey in the Northern District of California would best promote the “just and efficient conduct” of the litigation, the panel ruled. 

It said the multiple actions involve common factual issues arising from nearly identical questions about McKinsey’s role in providing advice to certain opioid manufacturers, most notably Purdue. 

The claims against McKinsey accuse it of public nuisance, negligence, negligent misrepresentation, fraud, unjust enrichment and violation of consumer protection statutes, the panel’s order says.

McKinsey provided its services in the form of sales and marketing strategies aimed at increasing sales of prescription opioid drugs. It has already struck more than $573 million in settlements over the claims.

The deal was reached in February with attorneys general in 47 states, five territories and the District of Columbia after legal filings revealed McKinsey was promoting and pushing prescriptions to opioid painkillers. 

In addition to paying out a total of $600 million, McKinsey agreed to releasing all its documents relating to the opioid scandal. Arizona Attorney General Mark Brnovich says there are tens of thousands of these internal documents following allegations some of its partners were destroying paper trails. 

What do you think of the claims against McKinsey? Let us know in the comments! 

The McKinsey Opioid Multidistrict Litigation Decision is In re: McKinsey & Co. Inc., National Prescription Opiate Consultant Litigation, Case No. 2996, in the Judicial Panel on Multidistrict Litigation.


Don’t Miss Out!

Check out our list of Class Action Lawsuits and Class Action Settlements you may qualify to join!


Read About More Class Action Lawsuits & Class Action Settlements:

We tell you about cash you can claim EVERY WEEK! Sign up for our free newsletter.

31 thoughts onOpioid Lawsuits Against Marketing Consultant McKinsey Get Own Multidistrict Litigation

  1. Wanda Matos says:

    How can I get added to this lawsuit

  2. Kelley Carlson says:

    Howvcan I get added or involved in this?

  3. Toby Ridenhour says:

    Please add me I’ve been struggling on pain medication since 1997. Between big pharmaceutical and the Dr’s this crisis will be revolving because it wasn’t us patients with the true issues and need for pain meds who were abusing them so when we need them not just because our body’s are naturally addicted but because we truly are in pain. PLEASE ADD ME TO THIS LAW SUIT.

  4. Robert Horton says:

    Please add me I’ve been struggling on pain medication for 14 years almost and between big pharmaceutical and the drs this crisis will be revolving because it wasn’t us patients with the true issues and need for pain meds who were abusing them so when we need them not just because our body’s are naturally addicted but because we truly are in pain ,, I’m 33 years old so almost all my adult life I’ve been addicted to pain meds and i was promised these opioids would be wonderful and is always be on them for rest of my life please add me

  5. Karen Madewell says:

    Please add me

  6. Jen Helmar says:

    Please add me

  7. Diane Vincent says:

    My husband is now deceased because of this
    Add me

  8. JOE EZELL says:

    Please add me

  9. TERI MATHEWS says:

    Add me.

  10. Eresa Pokorny says:

    Please add! Gone to Hell and back.

Leave a Reply

Your email address will not be published. By submitting your comment and contact information, you agree to receive marketing emails from Top Class Actions regarding this and/or similar lawsuits or settlements, and/or to be contacted by an attorney or law firm to discuss the details of your potential case at no charge to you if you qualify. Required fields are marked *

Please note: Top Class Actions is not a settlement administrator or law firm. Top Class Actions is a legal news source that reports on class action lawsuits, class action settlements, drug injury lawsuits and product liability lawsuits. Top Class Actions does not process claims and we cannot advise you on the status of any class action settlement claim. You must contact the settlement administrator or your attorney for any updates regarding your claim status, claim form or questions about when payments are expected to be mailed out.